Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Accumulated Expenses (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Accumulated Expenses for 2 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 70.84% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 70.84% year-over-year, with the annual reading at $3.3 million for FY2025, 70.84% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $3.3 million at Pyxis Oncology, down from $8.0 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $14.1 million in Q3 2024, with the low at $3.3 million in Q4 2025.